Regeneron’s stock is having its worst day in 14 years after the failure of late-stage trial of its COPD treatment, after analysts had just placed a high probability of a positive result.

Regeneron Pharmaceuticals (REGN) has been in a persistent downtrend for over 280 days. The stock is currently in the 10th Phase of its 18-Phase Adhishthana Cycle, our proprietary cyclical framework.

Regeneron Pharmaceuticals has a price-to-sales (P/S) ratio of 4.6 versus a figure of 3.0 for the S&P 500 Moreover, the company’s price-to-free cash flow (P/FCF) ratio stands at 16.4 in contrast ...

After a seven-day trial, jurors sided with Regeneron on 10 of 11 claims, and awarded $135.6 million in compensatory damages—the top end of what Regeneron’s expert suggested—and another $271. ...

Regeneron's purchase is still subject to court approval. If it gets a green light, as expected, the company could gain access to genetic data from more than 15 million 23andMe customers worldwide.

Regeneron announced the purchase Monday. In March, 23andMe initiated voluntary Chapter 11 proceedings in the U.S. Bankruptcy Court to be sold. 23andMe offers DNA testing with an ancestry breakdown ...

Regeneron’s deal to acquire 23andMe is still subject to approval in the U.S. Bankruptcy Court for the Eastern District of Missouri. A hearing in the case was scheduled for June 17.

Regeneron Pharmaceuticals’ $256 million offer was chosen the winner of 23andMe’s bankruptcy auction. Drug research never became a big part of the genetic testing company’s business, but it ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection.

Regeneron Pharmaceuticals agreed to purchase 23andMe for $256 million in a bankruptcy court auction, the company said Monday. The move allows 23andMe to continue to provide DNA testing services.